Lifitegrast
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease[1].
Product Specifications
CAS Number
[1025967-78-5]
Product Name Alternative
SAR 1118; SHP-606
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Integrin
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Lifitegrast.html
Purity
99.29
Solubility
DMSO : ≥ 29 mg/mL
Smiles
O=C(O)[C@H](CC1=CC=CC(S(=O)(C)=O)=C1)NC(C2=C(Cl)C3=C(CN(C(C4=CC=C5C=COC5=C4)=O)CC3)C=C2Cl)=O
Molecular Formula
C29H24Cl2N2O7S
Molecular Weight
615.48
Precautions
H302, H312, H332
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
αLβ2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human PIP5K1A shRNA (UAS) - Lentiviral human PIP5K1A shRNA (UAS, RFP) (100)
